Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The agilon health, inc. (AGL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. agilon health describes itself as a trusted partner empowering physicians to transition senior patients to a value-based Total Care Model, and its filings offer detail on how this business is structured and governed.
Investors can review current and historical reports such as Form 8-K filings, where agilon health has reported items including quarterly financial results, leadership transitions, amendments to by-laws, and notices related to New York Stock Exchange continued listing standards. These documents give additional context to the company’s announcements about its operations, value-based care arrangements, and corporate governance.
Through its periodic reports referenced in these filings, agilon health discusses topics such as risk factors associated with its value-based care model, relationships with payors and physician partners, and its reliance on medical services as a source of revenue. The filings may also describe compensation and employment arrangements for key executives, as reflected in agreements disclosed in Form 8-K exhibits.
On Stock Titan, users can combine direct access to agilon health’s SEC documents with AI-powered tools that summarize key points and highlight important sections. This can help readers more quickly understand complex disclosures related to financial performance, listing status, executive arrangements, and other matters that affect agilon health’s value-based healthcare business.
FMR LLC (Fidelity) and Chair & CEO Abigail P. Johnson filed a Schedule 13G reporting a passive 9.4 % stake in agilon health, Inc. (AGL) as of 30 Jun 2025. The group beneficially owns 38,760,723 common shares, with FMR holding sole voting power over 38,742,056 shares and sole dispositive power over the full position; no shared voting or dispositive rights were disclosed. The filing was made under Rule 13d-1(b) for a parent holding company/control person, indicating the shares were acquired in the ordinary course of business and not to influence control of the issuer. No other individual investor within the Fidelity complex owns more than 5 % of AGL. The declaration, signed 5 Aug 2025 by attorney-in-fact Richard Bourgelas, certifies passive intent. While the disclosure does not signal corporate action, it materially raises AGL’s institutional ownership base and may enhance liquidity and market visibility.
agilon health (AGL) filed an 8-K covering multiple governance and disclosure items. On 29 Jul 2025 Chief Executive Officer & President Steven J. Sell resigned, classified as a termination without “cause.” He will receive contractual severance; details reference the 2025 proxy. The Board size falls to seven and an “Office of the Chairman” is established, led by Executive Chairman Ron Williams and six other senior officers; CFO Jeffrey Schwaneke and Chief Markets Officer Benjamin Shaker become interim principal executive officers.
Concurrently, the Board amended and restated the company by-laws to redefine certain officer roles and incorporate technical Delaware law updates (filed as Ex. 3.1). Under Items 2.02 and 7.01 the company furnished—but did not file—press releases and an investor presentation (Exs. 99.1-99.3) containing Q2 2025 results and leadership changes; specific financial metrics are not included in this filing.
No related-party transactions were disclosed beyond existing indemnification agreements. Overall, the filing highlights a sudden CEO departure, interim leadership measures, and administrative charter updates.